Taken together, our data show that blocking PDGF-CC in MS-like neuroinflammation decreases endothelial cell activation and downregulates Tnfa and Il1a at the BBB, which in turn preserves the integrity of the BBB and ameliorates the disease. This evidence concerns the gene TNF and myeloid sarcoma.